Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Oxford Haemophilia & Thrombosis Centre; NIHR Oxford Biomedical Research Centre

University of Aberdeen; Thrombosis & Haemostasis laboratory

Social media

Gael Morrow

Research Fellow

My main research interest lies in fibrinolysis (degradation of a blood clot) and how the clot structure alters the rate of lysis in both inherited and acquired bleeding disorders.

Major bleeding during traumatic injury is exacerbated by a clotting abnormality termed trauma induced coagulopathy (TIC). TIC occurs in 25% of all injury-related deaths and results in an increased need for major haemorrhage therapy and a 3-4 fold increased risk of death. My current research focusses on understanding the cellular and molecular mechanisms that drive TIC and investigating differences in clot strength and structure between different blood product replacement therapies.

I am also investigating the haemostatic potential of extravascular Factor IX (FIX). Haemophilia B is a blood clotting disorder caused by deficiency of FIX, which is treated by infusion of FIX concentrates. The pharmacokinetics of FIX are complex and it is rapidly redistributed from the circulation following infusion. My research investigates FIX binding to collagen IV, an extracellular component of the endothelial membrane, and whether the FIX is active when bound to collagen IV.

Recent publications

More publications